Zai Lab stock is due for November 5 results

Published on 10/15/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 106.31 million, down 8.43 percent year over year. Zai Lab stock costs EUR 21.10 on October 15, 2026.

Upcoming results and valuation

The next report is estimated for November 5, 2026, before the market opens.
Second-quarter revenue reached USD 106.31 million versus USD 116.10 million a year earlier.
Zai Lab stock costs EUR 21.10 at Lang & Schwarz on October 15, 2026 at 9:40 p.m. CEST.
Zai Lab had a market capitalization of USD 2.6 billion as of October 15, 2026.

ZLAB, US98887Q1040, Illustration mit AI erstellt.

MarketBeat estimates that Zai Lab will report third-quarter 2026 results on November 5, 2026, before the market opens. The date gives investors the next scheduled checkpoint for revenue and earnings expectations. Zai Lab stock was trading at EUR 21.10 at Lang & Schwarz on October 15, 2026 at 9:40 p.m. CEST.

Revenue sets the next comparison

Zai Lab reported USD 106.31 million in revenue for the second quarter of 2026, according to MarketBeat. The same source lists USD 116.10 million for the year-earlier quarter, which implies an 8.43 percent decline on that basis. Standardized financial data also put second-quarter net income attributable to common shareholders at a loss of USD 50.83 million and diluted earnings per share at minus USD 0.50.

Price position after the US session

The Nasdaq quote stood at USD 23.55 at 3:46 p.m. EDT on October 15, 2026, up 4.67 percent from USD 22.50. The session volume was 605,136 shares against an average of 931,100 shares. Zai Lab's 52-week range was USD 15.96 to USD 30.00, placing the quote 21.50 percent below the high.

Valuation and reporting date

Zai Lab's market capitalization was USD 2.6 billion as of October 15, 2026. The quoted trailing price-to-earnings ratio was negative 13.12, while the dividend yield was 0.00 percent. The November 5 reporting date is estimated for before the market opens, with an 8:00 a.m. ET conference call.

Comparison with peers

Zai Lab (Nasdaq, USD): plus 4.67 percent, P/E negative 13.12, market capitalization USD 2.6 billion

Regeneron Pharmaceuticals (Nasdaq, USD): plus 2.79 percent, P/E 19.77, market capitalization USD 82.4 billion

Gilead Sciences (Nasdaq, USD): plus 3.15 percent, P/E negative 59.32, market capitalization USD 196.4 billion

Trading level and next date

The euro quotation gives German investors a separate view of the Nasdaq-listed biotech. The more useful near-term marker is the November reporting date, because the second-quarter revenue comparison showed USD 106.31 million against USD 116.10 million a year earlier.

The further course of trading is shown by the continuously updated real-time quote of Zai Lab stock.